Metformin-stimulated AMPK-α1 promotes microvascular repair in acute lung injury

American Journal of Physiology - Lung Cellular and Molecular Physiology

Volumn 305, Issue 11, 2013, Pages

  Jian, Ming Yuan ^a,c   Alexeyev, Mikhail F ^d,e   Wolkowicz, Paul E ^a,c   Zmijewski, Jaroslaw W ^b,c   Creighton, Judy R ^a,c  

^a Cleveland Clinic Main Campus   (United States)

^b Division of Pulmonary   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY OF SOUTH ALABAMA   (United States)

Author keywords

Acute respiratory distress syndrome; Edema; Endothelium; Lipopolysaccharide; Permeability; Sepsis

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; AMP ACTIVATED PROTEIN KINASE ALPHA1; ENDOTOXIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; LIPOPOLYSACCHARIDE; METFORMIN; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG;

ACUTE LUNG INJURY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL PERMEABILITY; CAPILLARY ENDOTHELIAL CELL; CONTROLLED STUDY; ELECTRIC RESISTANCE; EX VIVO STUDY; FILTRATION; IN VITRO STUDY; IN VIVO STUDY; ISOLATED LUNG; LUNG EDEMA; MICROVASCULAR ENDOTHELIAL CELL; MICROVASCULARIZATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; STIMULATION; WOUND HEALING;

ACUTE RESPIRATORY DISTRESS SYNDROME; EDEMA; ENDOTHELIUM; LIPOPOLYSACCHARIDE; PERMEABILITY; SEPSIS;

AMINOIMIDAZOLE CARBOXAMIDE; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; CELL MEMBRANE PERMEABILITY; CELL MOVEMENT; CELLS, CULTURED; ELECTRIC IMPEDANCE; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; ENZYME ACTIVATION; GENE KNOCKDOWN TECHNIQUES; LIPOPOLYSACCHARIDES; LUNG; MALE; METFORMIN; MICROVESSELS; PYRAZOLES; PYRIMIDINES; RATS; RATS, SPRAGUE-DAWLEY; RESPIRATORY DISTRESS SYNDROME, ADULT; RIBONUCLEOTIDES; RNA, SMALL INTERFERING; WOUND HEALING;

EID: 84889005964     PISSN: 10400605     EISSN: 15221504     Source Type: Journal    
DOI: 10.1152/ajplung.00173.2013     Document Type: Article

References (42)

1. Baines D. Kinases as targets for ENaC regulation. Curr Mol Pharmacol 6: 50-64, 2013.
2. Boyle JG, Salt IP, McKay GA. Metformin action on AMP-activated protein kinase: a translational research approach to understanding a potential new therapeutic target. Diabet Med 27: 1097-1106, 2010.
3. Creighton J. Targeting therapeutic effects: subcellular location matters. Focus on "Pharmacological AMP-kinase activators have compartmentspecific effects on cell physiology". Am J Physiol Cell Physiol 301: C1293-C1295, 2011.
4. Creighton J, Jian M, Sayner S, Alexeyev M, Insel PA. Adenosine monophosphate-activated kinase α1 promotes endothelial barrier repair. FASEB J 25: 3356-3365, 2011.
5. Ewart MA, Kennedy S. AMPK and vasculoprotection. Pharmacol Ther 131: 242-253, 2011.
6. Gong MN, Thompson BT, Williams P, Pothier L, Boyce PD, Christiani DC. Clinical predictors of and mortality in acute respiratory distress syndrome: potential role of red cell transfusion. Crit Care Med 33: 1191-1198, 2005.
7. +) channels and AMPK activation. Mol Cell Biol 31: 3546-3556, 2011.
8. Hardie DG, Ross FA, Hawley SA. AMP-activated protein kinase: a target for drugs both ancient and modern. Chem Biol 19: 1222-1236, 2012.
9. Hawley SA, Fullerton MD, Ross FA, Schertzer JD, Chevtzoff C, Walker KJ, Peggie MW, Zibrova D, Green KA, Mustard KJ, Kemp BE, Sakamoto K, Steinberg GR, Hardie DG, Steinberg GR, Kemp BE, Galic S, Fullerton MD, Schertzer JD, Sikkema S, Marcinko K, Walkley CR, Izon D, Honeyman J, Chen ZP, van Denderen BJ, Kemp BE, Steinberg GR. The ancient drug salicylate directly activates AMPactivated protein kinase. Science 336: 918-922, 2012.
10. Honiden S, Gong MN. Diabetes, insulin, and development of acute lung injury. Crit Care Med 37: 2455-2464, 2009.
11. Insel PA, Patel HH. Membrane rafts and caveolae in cardiovascular signaling. Curr Opin Nephrol Hypertens 18: 50-56, 2009.
12. Iscimen R, Cartin-Ceba R, Yilmaz M, Khan H, Hubmayr RD, Afessa B, Gajic O. Risk factors for the development of acute lung injury in patients with septic shock: an observational cohort study. Crit Care Med 36: 1518-1522, 2008.
13. King J, Hamil T, Creighton J, Wu S, Bhat P, McDonald F, Stevens T. Structural and functional characteristics of lung macro-and microvascular endothelial cell phenotypes. Microvasc Res 67: 139-151, 2004.
14. Levitt JE, Matthay MA. Clinical review: Early treatment of acute lung injury - paradigm shift toward prevention and treatment prior to respiratory failure. Crit Care 16: 223, 2012.
15. Lowe K, Alvarez D, King J, Stevens T. Phenotypic heterogeneity in lung capillary and extra-alveolar endothelial cells. Increased extra-alveolar endothelial permeability is sufficient to decrease compliance. J Surg Res 143: 70-77, 2007.
16. Matthay MA, Ware LB, Zimmerman GA. The acute respiratory distress syndrome. J Clin Invest 122: 2731-2740, 2012.
17. Matthay MA, Zimmerman GA, Esmon C, Bhattacharya J, Coller B, Doerschuk CM, Floros J, Gimbrone MA Jr, Hoffman E, Hubmayr RD, Leppert M, Matalon S, Munford R, Parsons P, Slutsky AS, Tracey KJ, Ward P, Gail DB, Harabin AL. Future research directions in acute lung injury: summary of a National Heart, Lung, and Blood Institute working group. Am J Respir Crit Care Med 167: 1027-1035, 2003.
18. Matute-Bello G, Downey G, Moore BB, Groshong SD, Matthay MA, Slutsky AS, Kuebler WM. An official American Thoracic Society workshop report: features and measurements of experimental acute lung injury in animals. Am J Respir Cell Mol Biol 44: 725-738, 2011.
19. Matute-Bello G, Frevert CW, Martin TR. Animal models of acute lung injury. Am J Physiol Lung Cell Mol Physiol 295: L379-L399, 2008.
20. Moss M, Guidot DM, Steinberg KP, Duhon GF, Treece P, Wolken R, Hudson LD, Parsons PE. Diabetic patients have a decreased incidence of acute respiratory distress syndrome. Crit Care Med 28: 2187-2192, 2000.
21. National Library of Medicine. DailyMed. Bethesda, MD: U.S. National Library of Medicine, National Institutes of Health, Health & Human Services.
22. Patel HH, Murray F, Insel PA. Caveolae as organizers of pharmacologically relevant signal transduction molecules. Annu Rev Pharmacol Toxicol 48: 359-391, 2008.
23. Patel HH, Murray F, Insel PA. G-protein-coupled receptor-signaling components in membrane raft and caveolae microdomains. Handb Exp Pharmacol 167-184, 2008.
24. Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, Camporota L, Slutsky AS. Acute respiratory distress syndrome: the Berlin Definition. JAMA 307: 2526-2533, 2012.
25. Salt IP, Palmer TM. Exploiting the anti-inflammatory effects of AMPactivated protein kinase activation. Expert Opin Invest Drugs 21: 1155-1167, 2012.
26. Steinberg GR, Kemp BE. AMPK in health and disease. Physiol Rev 89: 1025-1078, 2009.
27. Stevens T. Functional and molecular heterogeneity of pulmonary endothelial cells. Proc Am Thorac Soc 8: 453-457, 2011.
28. Stevens T, Phan S, Frid MG, Alvarez D, Herzog E, Stenmark KR. Lung vascular cell heterogeneity: endothelium, smooth muscle, and fibroblasts. Proc Am Thorac Soc 5: 783-791, 2008.
29. Tadie JM, Bae HB, Deshane JS, Bell CP, Lazarowski ER, Chaplin DD, Thannickal VJ, Abraham E, Zmijewski JW. Toll-like receptor 4 engagement inhibits adenosine 5'-monophosphate-activated protein kinase activation through a high mobility group box 1 protein-dependent mechanism. Mol Med 18: 659-668, 2012.
30. Vadasz I, Sznajder JI. Update in acute lung injury and critical care 2010. Am J Respir Crit Care Med 183: 1147-1152, 2011.
31. Viollet B, Andreelli F. AMP-activated protein kinase and metabolic control. Handb Exp Pharmacol 303-330, 2011.
32. Viollet B, Athea Y, Mounier R, Guigas B, Zarrinpashneh E, Horman S, Lantier L, Hebrard S, Devin-Leclerc J, Beauloye C, Foretz M, Andreelli F, Ventura-Clapier R, Bertrand L. AMPK: Lessons from transgenic and knockout animals. Front Biosci 14: 19-44, 2009.
33. Viollet B, Guigas B, Sanz Garcia N, Leclerc J, Foretz M, Andreelli F. Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond) 122: 253-270, 2012.
34. Viollet B, Horman S, Leclerc J, Lantier L, Foretz M, Billaud M, Giri S, Andreelli F. AMPK inhibition in health and disease. Crit Rev Biochem Mol Bio 45: 276-295, 2010.
35. Wang S, Song P, Zou MH. AMP-activated protein kinase, stress responses and cardiovascular diseases. Clin Sci (Lond) 122: 555-573, 2012.
36. Wiener-Kronish JP, Pittet JF. Therapies against virulence products of Staphylococcus aureus and Pseudomonas aeruginosa. Semin Respir Crit Care Med 32: 228-235, 2011.
37. + transport processes across human lung epithelial cells. Br J Pharmacol 151: 1204-1215, 2007.
38. Xing J, Wang Q, Coughlan K, Viollet B, Moriasi C, Zou MH. Inhibition of amp-activated protein kinase accentuates lipopolysaccharideinduced lung endothelial barrier dysfunction and lung injury in vivo. Am J Pathol 182: 1021-1030, 2013.
39. Yamashita CM, Lewis JF. Emerging therapies for treatment of acute lung injury and acute respiratory distress syndrome. Expert Opin Emerg Drugs 17: 1-4, 2012.
40. Zhang Y, Wang Y, Bao C, Xu Y, Shen H, Chen J, Yan J, Chen Y. Metformin interacts with AMPK through binding to gamma subunit. Mol Cell Biochem 368: 69-76, 2012.
41. Zhao X, Zmijewski JW, Lorne E, Liu G, Park YJ, Tsuruta Y, Abraham E. Activation of AMPK attenuates neutrophil proinflammatory activity and decreases the severity of acute lung injury. Am J Physiol Lung Cell Mol Physiol 295: L497-L504, 2008.
42. Zmijewski JW, Lorne E, Zhao X, Tsuruta Y, Sha Y, Liu G, Siegal GP, Abraham E. Mitochondrial respiratory complex I regulates neutrophil activation and severity of lung injury. Am J Respir Crit Care Med 178: 168-179, 2008.